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INTRODUCTION
External-cause mortality is one of the leading causes of death 
worldwide.1 These deaths, including suicide, homicide, acci-
dents, and injuries, account for 12.8% (65.6/100000 persons) 
of all deaths in the Republic of Korea, and are the third leading 
cause of death, following cancer (144.4/100000 persons) and 
cardiovascular disease (112.5/100000 persons), according to 
2010 data.2
The possible association between death from external causes 
and serum total cholesterol has been suggested since the 1990s.3 
Although findings on cardiovascular risk factors are still con-
tradictory, numerous studies report an association between 
cardiovascular risk factors, such as diabetes, obesity, and serum 
total cholesterol, and the risk of external-cause mortalities, 
such as suicide.4,5 
Clinical and epidemiological studies have reported an asso-
ciation between elevated liver enzymes, such as gamma-glu-
tamyltransferase, alkaline phosphatase, alanine aminotransfer-
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ase (ALT), and aspartate aminotransferase (AST), with non-
liver-related mortality and morbidity, including cardiovascular 
disease.6,7 Although elevated liver enzymes are also associated 
with several factors, such as alcohol intake, viral hepatitis, and 
non-alcoholic fatty liver disease (NAFLD),8,9 they are strong 
predictors of cardiovascular disease, and are a hepatic mani-
festation of metabolic syndrome.10,11 Since cardiovascular risk 
factors are associated with external-cause mortalities, elevation 
of liver enzymes may also be associated with these deaths. 
This study investigated the effect of elevated serum amino-
transferase on overall and specific subtypes of external-cause 
mortality in a large, population-based cohort study in Korea 
by applying a competing risks regression analysis. 
MATERIALS AND METHODS
Study subjects
In Korea, all workers and their dependents are required to join 
compulsory National Health Insurance service and participate 
in biennial medical examinations performed by the National 
Health Insurance Corporation. A total of 94.5% and 94.4% of 
these individuals completed the biennial examinations in 1990 
and 1992, respectively. Our cohort consisted of all female work-
ers aged 35–59 years and a 25% systematic random sample of 
all insured male workers aged 35–59 years who completed a he-
alth examination in 1990 and 1992.12 After excluding cases of 
death before January 1, 1993, 108637 males and 64149 females 
were included in this study.
Data collection
Biennial examinations, including measurements of blood pres-
sure, serum total cholesterol, fasting blood glucose, ALT, AST, 
weight, and height, were conducted following a standardized 
protocol at 416 hospitals located throughout the Republic of 
Korea in 1990 and 1992. Each hospital adhered to internal and 
external quality control procedures directed by the Korean As-
sociation of Laboratory Quality Control. Self-reported surveys 
on smoking habits, alcohol intake, marital status, and subjec-
tive health status were conducted in 1992. This study was ap-
proved by the Institutional Review Board of Yonsei University 
Health System, Seoul, Korea (4-2004-0105), and the require-
ment for informed consent was waived because we used sec-
ondary data containing randomly generated identification 
numbers to mask the identities of the subjects.
Outcome measurements
Mortality from external causes was identified using death cer-
tificate data from the National Statistical Office from 1993 to 
2006. Deaths from external causes were classified into the fol-
lowing groups according to the International Classification of 
Diseases, 10th Revision: deaths from all internal causes (A00-
R99), deaths from all external causes (S00-Y98), and injury [fall 
(W00–W19), fires (X00–X09), poisonings (X40–X49), drowning 
(W65–W74), unintentional injuries (V90–V99, W20–W64, 
W75–W99, X10–X39, X50–X59)], and suicide (X60–X84). 
Statistical analysis
After excluding cases lacking smoking, alcohol intake, marital 
status, and subjective health status data (30258), 142322 indi-
viduals who completed biennial examinations in 1990 and in 
1992 were included in the analysis. Characteristics of the ex-
cluded and included subjects are shown in Supplementary Ta-
ble 1 (only online). With the exception of smoking status, alco-
hol intake, marital status, and subjective health status (which 
were measured in 1992 only), the average of two baseline 
measurements was used for analysis. 
Smoking status was defined as nonsmoker, ex-smoker, and 
current smoker. Alcohol intake was defined as non-drinker and 
quartiles according to grams of alcohol per day (<10.3, 10.3–
20.5, 20.6–30.8, or ≥30.9 g/day). Blood pressure was classified 
according to the guidelines of the Seventh Joint National Com-
mittee for the Detection, Evaluation, and Treatment of High 
Blood Pressure: normal [systolic blood pressure (SBP) <120 and 
diastolic blood pressure (DBP) <80 mm Hg], prehypertension 
(120≤SBP<140 or 80≤DBP<90 mm Hg), stage 1 hypertension 
(140≤SBP<160 or 90≤DBP<100 mm Hg), or stage 2 hyperten-
sion (160≤SBP or 100≤DBP mm Hg).13 
To investigate the association of serum aminotransferase 
levels with each specific type of death from external causes, we 
used competing risk regression analysis, which treated deaths 
from all other causes (e.g., deaths from internal causes) as com-
peting risks.14 We estimated cumulative incidences, sub-distri-
bution hazard ratios (SHRs), and 95% confidence intervals (CIs) 
of SHRs of all external-cause mortalities, as well as the suicide 
and injury subtypes.15 In the competing risk regression model, 
all potential confounding variables, such as age, sex, marital 
status, subjective health status, smoking status, alcohol intake, 
body mass index, blood pressure (JNC 7 classification), serum 
total cholesterol, and fasting blood glucose, were included. 
Due to potential effect modification between serum amino-
transferase level and alcohol intake on external cause mortal-
ity, subjects were divided into three groups based on alcohol 
intake: never or light (<10.3 g/day), moderate (≥10.3 and <30.9 
g/day), or heavy (≥30.9 g/day). Interaction effects were also 
examined after including the interaction term (quintiles of se-
rum aminotransferase level and alcohol intake) in the com-
peting risk regression model.
Since ALT and AST were closely correlated each other, all 
analyses were done separately. Due to relatively small num-
bers of deaths from external causes and no interaction effect 
between sex and serum aminotransferase level on external 
cause mortalities, analyses were not stratified by sex. 
The ‘cmprsk’ package version 2.2-1 (R software version 2.13.0) 
and SAS version 9.3 (SAS Institute, Cary, NC, USA) were used 
for analysis. 
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RESULTS
A total of 8808 deaths (7697 from internal causes and 1111 
from external causes) were reported during follow-up. Of the 
1111 from external causes, 255 (23.0%) died due to suicide 
and 256 (23.0%) due to injury. The majority of external-cause 
mortalities occurred in males (88.4%). Table 1 shows the base-
line characteristics of the subjects stratified by cause of death at 
follow-up. The proportions of current smokers, heavy drink-
ers, and pre-hypertensive or hypertensive patients were high-
er for subjects who died from external causes than for those 
who did not. 
Cumulative incidences of death from external causes, sui-
cide, or injury, respectively, were significantly higher in the hi-
ghest quintiles of AST and ALT, compared with the lowest quin-
tile (Fig. 1). After adjustments for covariates, the risk of death 
from external causes was significantly higher for subjects in 
the two highest quintiles (quintile 4 and quintile 5, respectively) 
of ALT and the highest quintile of AST, compared to the lowest 
respective quintiles (Table 2). The linear trend was also statis-
tically significant for both ALT (p<0.001) and AST (p<0.001). 
The risk of death from suicide or injury was also significantly 
increased for individuals in the higher quintiles of ALT and AST, 
with the highest risks being in quintile 5 for both enzymes.
The SHRs of death from all external causes and injury were 
significantly higher among heavy drinkers (≥30.9 g/day), com-
pared to non-drinkers, after adjusting for ALT and AST levels 
with other confounding factors: 1.42 (95% CI, 1.20–1.69) and 
Table 1. Baseline Characteristics of the Subjects According to Specific Causes of Death
Total
(n=142322)
Non-case
(n=133514)
Deaths from external causes
All causes
(n=1111)
Suicide
(n=255)
Injury
(n=256)
Age (yrs) 43.9±6.60 43.6±6.51 46.1±6.62 46.0±6.63 46.9±6.54
Sex, male (%) 94019 (66.1) 86297 (64.6) 982 (88.4) 221 (86.7) 231 (90.2)
Smoking status
Non-smoker 67758 (47.6) 65494 (49.1) 308 (27.7) 72 (28.2) 71 (27.7)
Ex-smoker 20152 (14.2) 18639 (14.0) 172 (15.5) 44 (17.3) 43 (16.8)
Current smoker 54412 (38.2) 49381 (37.0) 631 (56.8) 139 (54.5) 142 (55.5)
Marital status
Married 133435 (93.8) 125134 (93.7) 1048 (94.3) 229 (89.8) 247 (96.5)
Not married 3673 (2.6) 3559 (2.7) 19 (1.7) 10 (3.9) 1 (0.4)
Others 5214 (3.7) 4821 (3.6) 44 (4.0) 16 (6.3) 8 (3.1)
Subjective health status
Healthy 65254 (45.9) 61643 (46.2) 510 (45.9) 106 (41.6) 120 (46.9)
Unhealthy 51477 (36.2) 48748 (36.5) 359 (32.3) 92 (36.1) 75 (29.3)
Illness 14488 (10.2) 13557 (10.2) 120 (10.8) 25 (9.8) 25 (9.8)
Diseased 11103 (7.8) 9566 (7.2) 122 (11.0) 32 (12.6) 36 (14.1)
Drinking status
Non-drinker (0 g/day) 71375 (50.2) 68085 (51.0) 361 (32.5) 88 (34.5) 85 (33.2)
Q1 (<10.3 g/day) 15137 (10.6) 14157 (10.6) 132 (11.9) 40 (15.7) 24 (9.4)
Q2 (10.3–20.5 g/day) 17225 (12.1) 15362 (12.0) 165 (14.9) 32 (12.6) 37 (14.5)
Q3 (20.6–30.8 g/day) 21371 (15) 19587 (14.7) 234 (21.1) 47 (18.4) 51 (19.9)
Q4 (≥30.9 g/day) 17214 (12.1) 15723 (11.8) 219 (19.7) 48 (18.8) 59 (23.1)
Blood pressure
Normal 50674 (35.6) 48888 (36.6) 264 (23.8) 69 (27.1) 54 (21.1)
Pre-hypertension 60721 (42.7) 57007 (42.7) 527 (47.4) 117 (45.9) 117 (45.7)
Stage 1 hypertension 23938 (16.8) 21640 (16.2) 234 (21.1) 51 (20.0) 59 (23.1)
Stage 2 hypertension 6989 (4.9) 5989 (4.5) 86 (7.7) 18 (7.1) 26 (10.2)
Body mass index (kg/m2) 23.1±2.49 23.0±2.48 23.2±2.58 22.9±2.59 23.1 (2.71)
Serum total cholesterol (mg/L) 190.7±37.88 190.5±37.56 191.6±39.24 191.7±34.85 194.8±43.81
Fasting plasma glucose (mg/L) 90.4±20.86 89.8±19.25 96.1±29.65 95.8±30.37 100.6±40.81
ALT (IU/L) 22.4±19.76 21.9±18.50 25.8±20.62 25.7±18.34 26.3±22.55
AST (IU/L) 23.5±15.89 23.0±14.42 27.8±23.88 26.9±15.29 31.1±36.87
AST, aspartate aminotransferase; ALT, alanine aminotransferase.
Values are expressed as number and percentage or mean±standard deviation.
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1.36 (95% CI, 1.14–1.62) for all external causes and 1.76 (95% CI, 
1.24–2.50) and 1.67 (95% CI, 1.17–2.39) for injury, respectively. 
However, suicide mortality was not associated with alcohol in-
take. In the never or light alcohol intake group, the risks of sui-
cide and injury deaths were significantly increased in the high-
est ALT quintile, although the risk of all external-cause mortality 
was not associated with ALT (Table 3). In the moderate or heavy 
alcohol intake group, the risks of external-cause mortality and 
injury were significantly increased in the high ALT quintiles, 
and the linear trend of the association between suicide risk 
and ALT approached significance (p=0.05). The risk of external-
cause death was significantly increased in quintile 5 of AST in 
the never or light and the moderate alcohol intake groups, and 
linear trends showed a significant association between AST and 
external-cause mortality in all three alcohol intake groups (Ta-
ble 4). Although linear trends were observed, the risk of death 
from suicide and injury was not significantly increased in high 
AST quintiles, compared to quintile 1. No interaction effects 
were observed between serum aminotransferase levels and al-
cohol intake for any type of external-cause death. 
DISCUSSION 
Until recently, although many clinical and epidemiologic stud-
ies have investigated the effect of cardiovascular risk factors 
on external-cause mortalities (e.g., suicide and injury), the ef-
fect of elevated liver enzymes has not been explored. In the pre-
sent study, we used a large prospective cohort to investigate 
the association between serum aminotransferase levels and 
external-cause mortality and found that elevated serum amino-
transferase levels, even within normal range, substantially in-
creased the risk of death from all external causes, suicide, and 
injury. 
Table 2. Sub-Distribution Hazard Ratios (SHRs) of Death from All External Causes, Suicide, and Injury
SHR (95% CI)
All external causes (n=1111) Suicide (n=255) Injury (n=256)
 ALT
Quintile 1 (≤14.0 IU/L) 1.00 1.00 1.00
Quintile 2 (14.1–17.5 IU/L) 1.18 (0.94–1.48) 2.10 (1.26–3.48) 1.07 (0.65–1.77)
Quintile 3 (17.6–21.5 IU/L) 1.14 (0.91–1.42) 1.33 (0.77–2.29) 1.42 (0.89–2.28)
Quintile 4 (21.6–27.5 IU/L) 1.27 (1.08–1.60) 2.13 (1.28–3.57) 1.22 (0.74–2.00)
Quintile 5 (>27.5 IU/L) 1.57 (1.26–1.95) 2.73 (1.68–4.46) 1.79 (1.10–2.90)
p for trend <0.001 0.001 0.012
 AST
Quintile 1 (≤17.0 IU/L) 1.00 1.00 1.00
Quintile 2 (17.1–20.0 IU/L) 0.89 (0.71–1.11) 1.02 (0.63–1.65) 1.00 (0.61–1.64)
Quintile 3 (20.1–23.5 IU/L) 0.90 (0.73–1.12) 1.22 (0.78–1.91) 1.39 (0.89–2.16)
Quintile 4 (23.6–28.0 IU/L) 1.14 (0.92–1.39) 1.46 (0.93–2.28) 1.15 (0.72–1.83)
Quintile 5 (>28.0 IU/L) 1.45 (1.20–1.76) 1.75 (1.15–2.66) 1.85 (1.21–2.82)
p for trend <0.001 <0.001 <0.001
AST, aspartate aminotransferase; ALT, alanine aminotransferase; CI, confidence interval.
The competing regression model included age, sex, marital status, subjective health status, smoking status, alcohol intake, blood pressure (JNC 7 classification), 
body mass index, serum total cholesterol, fasting blood glucose, ALT (or AST), and AST-ALT ratio (≤2 or >2). 
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Fig. 1. Cumulative incidences of deaths from external causes based on (A) serum alanine aminotransferase and (B) aspartate aminotransferase stratified 
into quintiles.
A B
http://dx.doi.org/10.3349/ymj.2015.56.6.15821586
Liver Enzymes and External Causes Mortality
Serum aminotransferase has been used since 1955 to diag-
nose liver diseases, such as viral hepatitis, and it is used today 
to screen for alcohol abuse or determine liver and pancreatic 
function in primary care settings. Recently, the majority of liv-
er test abnormalities are attributed to the presence of alcohol-
ic or NAFLD.16 Although liver enzyme measurements show rel-
atively low sensitivity and may therefore underestimate the 
prevalence of NAFLD, ALT is closely related to fat accumula-
tion in the liver and visceral adipose tissue in both Western 
and Asian countries.17,18 
In the present study, higher ALT and AST levels were asso-
ciated with increased external-cause mortality, suicide, and in-
jury in a dose-dependent manner. Even though ALT was within 
the normal range in quintile 4 (21.7–27.5 IU/L), the risk of death 
from external causes (SHR, 1.27; 95% CI, 1.08–1.60) and suicide 
(SHR, 2.13; 95% CI, 1.28–3.57) was significantly increased, 
compared to the lowest quintile (≤14.0 IU/L). Although the ob-
servational nature of our study makes it difficult to fully explain 
our results, increased external-cause mortality risk may be at-
tributed to the morbidity of cardiovascular disease, diabetes 
mellitus (DM), or cancer in association with liver enzyme ele-
vations. Many epidemiologic and clinical studies have shown 
that elevated liver enzymes, even within the normal range, are 
associated with increased risks of coronary artery disease, ath-
erosclerosis, hypertension, insulin resistance, and type 2 DM, 
as well as overall mortality, and that they may serve as surro-
gates for morbidity or mortality.19-21 Our previous study also 
highlighted an association between elevated liver enzymes 
and the risks of all-cause and cause-specific mortalities, such as 
cancer and cardiovascular diseases.7 Many studies have also 
suggested an association between death from external causes, 
(suicide and injury) with cardiovascular disease and related 
risk factors.4,5 
Among the elderly, physical illnesses, such as DM and car-
diovascular diseases, are significantly associated with the risk 
of hospitalization or death from falls, suicide, or suicide at-
tempts,22-24 with stroke in particular being an important risk fac-
tor for suicide.25,26 Although biological mechanisms for these 
associations are not fully understood, cardiovascular disease, 
DM, and metabolic syndrome are frequently accompanied by 
brain dysfunction, such as depression, cognitive decline, and 
other psychiatric illness.27-30 Other mechanisms, such as in-
flammation, hypoperfusion, and disconnection of neural con-
nectivity due to focal vascular damage, have been proposed in 
the pathogenesis of cognitive impairment, depression, and en-
dothelial damage in regional cerebral blood flow.31,32 Depres-
sion is a major risk factor of suicide mortality, and cognitive de-
cline is significantly associated with high risk of injury, includ-
ing falls.33-35 As liver enzyme elevation is associated with mor-
bidity related to cardiovascular diseases, DM, insulin resist-
ance, and cancer, it may also be associated with increased risk 
of external-cause mortality.
Table 3. Sub-Distribution Hazard Ratios (SHRs) of All External-Cause Mortality, Suicide, and Injury Stratified by Alcohol Intake
ALT
Alcohol intake p for 
interactionNever or light (<10.3 g/day) Moderate (10.3–30.8 g/day) Heavy (≥30.9 g/day)
All external causes
Quintile 1 (≤14.0 IU/L) 1.00 1.00 1.00 <0.001
Quintile 2 (14.1–17.5 IU/L) 1.16 (0.86–1.55) 1.43 (0.92–2.24) 0.90 (0.48–1.68)
Quintile 3 (17.6–21.5 IU/L) 0.92 (0.67–1.25) 1.62 (1.06–2.48) 1.12 (0.63–2.01)
Quintile 4 (21.6–27.5 IU/L) 1.08 (0.79–1.48) 1.67 (1.10–2.55) 1.29 (0.74–2.26)
Quintile 5 (>27.5 IU/L) 1.25 (0.91–1.71) 2.10 (1.39–3.19) 1.62 (0.94–2.78)
p for trend 0.291 <0.001 0.007
Suicide
Quintile 1 (≤14.0 IU/L) 1.00 1.00 1.00 0.192
Quintile 2 (14.1–17.5 IU/L) 2.52 (1.30–4.87) 1.20 (0.47–3.07) 3.00 (0.65–13.79)
Quintile 3 (17.6–21.5 IU/L) 1.39 (0.66–2.91) 1.02 (0.40–2.58) 1.86 (0.37–9.26)
Quintile 4 (21.6–27.5 IU/L) 2.73 (1.40–5.35) 1.30 (0.52–3.21) 2.35 (0.51–10.89)
Quintile 5 (>27.5 IU/L) 2.42 (1.23–4.76) 2.05 (0.87–4.80) 4.64 (1.12–19.18)
p for trend 0.026 0.055 0.028
Injury
Quintile 1 (≤14.0 IU/L) 1.00 1.00 - 0.049
Quintile 2 (14.1–17.5 IU/L) 0.83 (0.43–1.61) 3.87 (1.13–13.3) -
Quintile 3 (17.6–21.5 IU/L) 0.98 (0.52–1.85) 3.93 (1.16–13.3) -
Quintile 4 (21.6–27.5 IU/L) 0.92 (0.46–1.82) 2.46 (0.69–8.77) -
Quintile 5 (>27.5 IU/L) 1.35 (0.69–2.63) 5.12 (1.49–17.6) -
p for trend 0.319 0.041 -
-, non-calculable. 
Alanine aminotransferase (ALT) levels were divided into quintiles. Competing regression model included age, sex, marital status, subjective health status, smok-
ing status, blood pressure (JNC 7 classification), body mass index, serum total cholesterol, fasting blood glucose, and ALT.
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Table 4. Sub-Distribution Hazard Ratios (SHRs) of Death from All External Causes, Suicide, and Injury Stratified by Alcohol Intake
AST
Alcohol intake p for 
interactionNever or light (<10.3 g/day) Moderate (10.3–30.8 g/day) Heavy (≥30.9 g/day)
All external causes
Quintile 1 (≤17.0 IU/L) 1.00 1.00 1.00 0.006
Quintile 2 (17.1–20.0 IU/L) 0.89 (0.66–1.19) 0.81 (0.54–1.21) 1.13 (0.62–2.08)
Quintile 3 (20.1–23.5 IU/L) 0.91 (0.68–1.21) 0.80 (0.54–1.17) 1.19 (0.68–2.10)
Quintile 4 (23.6–28.0 IU/L) 1.01 (0.75–1.36) 1.37 (0.97–1.93) 1.05 (0.60–1.84)
Quintile 5 (>28.0 IU/L) 1.37 (1.04–1.81) 1.49 (1.06–2.09) 1.63 (0.98–2.71)
p for trend 0.022 <0.001 0.031
Suicide
Quintile 1 (≤17.0 IU/L) 1.00 1.00 1.00 0.243
Quintile 2 (17.1–20.0 IU/L) 1.20 (0.64–2.22) 0.61 (0.24–1.52) 1.49 (0.36–6.19)
Quintile 3 (20.1–23.5 IU/L) 1.51 (0.84–2.70) 0.77 (0.34–1.74) 1.33 (0.33–5.34)
Quintile 4 (23.6–28.0 IU/L) 1.56 (0.85–2.86) 1.11 (0.51–2.40) 1.94 (0.54–7.04)
Quintile 5 (>28.0 IU/L) 1.67 (0.94–2.98) 1.29 (0.62–2.68) 2.75 (0.82–9.27)
p for trend 0.047 0.138 0.041
Injury
Quintile 1 (≤17.0 IU/L) 1.00 1.00 0.141
Quintile 2 (17.1–20.0 IU/L) 0.70 (0.36–1.37) 1.29 (0.50–3.34) -
Quintile 3 (20.1–23.5 IU/L) 1.24 (0.70–2.18) 1.55 (0.64–3.79) -
Quintile 4 (23.6–28.0 IU/L) 0.62 (0.30–1.28) 2.17 (0.93–5.11) -
Quintile 5 (>28.0 IU/L) 1.80 (1.03–3.16) 2.09 (0.90–4.86) -
p for trend 0.066 0.027 -
-, non-calculable. 
Aspartate aminotransferase (AST) levels were divided into quintiles. Competing regression model included age, sex, marital status, subjective health status, 
smoking status, blood pressure (JNC 7 classification), body mass index, serum total cholesterol, fasting blood glucose, and AST.
The risk of external-cause mortality, especially suicide, may 
be associated with antiviral treatment, as interferon-α treat-
ment has been shown to be associated with increased risk of 
suicide or major depression in patients with hepatitis,36 and 
most trials report a 10% to 40% incidence of major depression 
during antiviral therapy.37 Hepatitis B virus infection is highly 
prevalent in Asia and Africa, and nationwide vaccination st-
rategies have been adopted to eliminate hepatitis B virus infec-
tion in Korea. According to 1998 data, the prevalence of hepati-
tis B in Korea was estimated at 5.1% in males and 4.1% in fe-
males.38 Hepatic encephalopathy is also directly associated 
with cognitive impairment in patients with viral hepatitis or 
alcoholic liver disease.39 Of the 1111 deaths from external cau-
ses in our study, 41 (3.7%) and 47 (4.2%) had been hospitalized 
for liver diseases and cancer, respectively, from 1993–2003, 
and two of these individuals had been hospitalized for con-
current liver disease and cancer. However, the actual number 
of patients who received antiviral treatment may be larger than 
our hospitalization records indicate, because patients usually 
receive antiviral treatment in an outpatient clinic. Neverthe-
less, our results may at least partly reflect the effect of antiviral 
treatment on external-cause mortality.
Alcohol intake is a major risk factor for both suicide and in-
jury.24,40 Compared to non-drinkers, heavy drinkers (>30.9 g/
day) showed an increased risk of external-cause mortality in 
our study. Due to the possibility of effect modification of alco-
hol intake on the association between liver enzymes and death 
from external causes, we further stratified subjects according 
to alcohol intake. In the never or light alcohol intake group, 
subjects with high AST demonstrated an increased risk of 
death from external cause, and those with high ALT showed 
an elevated risk of death from suicide and injury. However, no 
interaction effect of alcohol intake and serum aminotransfer-
ase levels on any external-cause mortality was observed. Re-
gardless of alcohol intake, elevated liver enzymes may increase 
the risk of death from external causes. 
Although we used a large population-based cohort, our study 
has some limitations. First, the relatively small number of 
deaths reported from external causes may limit the power of 
our study to correlate liver enzyme levels with external-cause 
mortality. Thus, the association of potential risk factors with 
death from specific external causes may have been uninten-
tionally overlooked due to insufficient statistical power. Sec-
ond, liver enzyme elevation also reflects comorbid conditions 
that are associated with cognitive or motor impairment, and 
may increase the risk of external-cause mortality, such as drug 
intoxication, cirrhosis, viral hepatitis, and hepatocellular car-
cinoma. We could not account for potentially confounding 
variables such as socioeconomic status and the use of subst-
ances other than tobacco and alcohol. However, because the 
study enrollees consisted of civil servants and private teach-
ers, substance use and variability in socioeconomic status 
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would be relatively low. Finally, reverse causation by preexist-
ing illness (e.g., psychiatric disorders) may affect study results, 
although we included subjective health status in the model to 
minimize this effect.
In conclusion, we analyzed the effects of serum aminotr-
ansferase levels on the risk of external-cause mortalities using 
a competing risk regression analysis. Elevated serum amino-
transferase levels, even within the normal range, substantially 
increased the risk of death from external causes, suicide, and 
injury, and this association was not influenced by alcohol in-
take. As elevations in liver enzyme are associated with meta-
bolic syndrome,10,11 we included confounding variables related 
to metabolic syndrome in the model and found that the ele-
vated liver enzymes were still significantly associated with ex-
ternal-causes mortality. These finding suggests that liver en-
zyme elevation could potentially be an early manifestation of 
external-causes mortality and clinically indicative of subtle 
brain dysfunction, which underscores a need to consider both 
cardiovascular and neuropsychiatric risks in individuals with 
elevated liver enzymes. Although serum aminotransferases 
are traditional markers with imperfect sensitivity and specifici-
ty, they could be taken as proxy indicators for the general popul-
ation, as assay of aminotransferases is cheap and widely avail-
able. Nonetheless, to confirm the noted relationship between 
liver enzymes and the risk of external-cause mortalities, a large 
prospective study that includes extensive information on blood 
chemistry and imaging (e.g., ultrasound for diagnosis of NA-
FLD) will be helpful.
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